# 該合作涵蓋一系列具有新穎差異化載體和多特異性抗體的抗體藥物偶聯物（ADC）。

*biotech · news · 2026-05-28 · Reuters*

## Key points

- 輝瑞將向信達支付6.5億美元的前期付款及最高98.5億美元的里程碑款項。
- 合作涵蓋12個抗體相關項目，包括信達的8個和輝瑞提出的4個。
- 信達將主導至第一期臨床開發，之後輝瑞接手全球開發責任。
- 四個項目將在美國和歐洲共同開發並共享利潤；信達保留大中華區權利。
- 其他項目中，輝瑞獲得全球或大中華區以外的獨家授權，成本責任有所不同。

The deal also includes a $650 million ​upfront payment to Innovent and up to $9.85 billion ⁠in potential development, regulatory and commercial milestone ​payments. Sign up here. The partnership spans a portfolio of antibody-drug conjugates (ADCs) with ​novel differentiated payloads and multi-specific antibodies, comprising eight Innovent-originated early-stage assets and four Pfizer-proposed discovery programs. Under the terms of the ​agreement, Innovent will lead development of the ​12 programs through Phase 1 clinical trials before Pfizer takes on ‌global ⁠development. The deal is structured across three tiers. Four programs will be co-developed and co-commercialised, with profits shared in the United States and Europe, while ​Innovent retains rights ​in Greater ⁠China. For another four programs, Pfizer receives an exclusive license outside Greater China, ​while it holds an exclusive global license ​and ⁠bears all global development costs for the remaining four. Innovent, together with its wholly-owned units Innovent Biologics (Suzhou) and ⁠Fortvita ​Biologics (USA) entered into the deal ​with Pfizer, the firm said in an exchange filing. Reporting by Rajasik ​Mukherjee & Sherin Sunny in Bengaluru; editing by Alan Barona

**Companies:** Pfizer, Innovent, Innovent Biologics (Suzhou), Fortvita Biologics (USA)
**Countries:** USA, China

[Read the full story on Reuters](https://www.reuters.com/legal/litigation/chinas-innovent-biologics-pfizer-strike-up-105-billion-cancer-drug-deal-2026-05-28/)

---

Canonical: https://newsio.io/zh-TW/n/b5ca3777-fbe6-45e0-8bf5-39fc0582bbc0/adc6-59
Summarized by Newsio from Reuters. https://newsio.io/how-it-works